Concepts (269)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antipsychotic Agents | 20 | 2024 | 48 | 9.570 |
Why?
|
| Child | 29 | 2024 | 657 | 3.910 |
Why?
|
| Medicaid | 14 | 2023 | 29 | 3.820 |
Why?
|
| Retrospective Studies | 51 | 2024 | 382 | 3.450 |
Why?
|
| Adolescent | 29 | 2024 | 806 | 3.190 |
Why?
|
| United States | 49 | 2024 | 521 | 3.090 |
Why?
|
| Analgesics, Opioid | 8 | 2024 | 74 | 2.940 |
Why?
|
| Humans | 86 | 2024 | 5476 | 2.940 |
Why?
|
| Psychotropic Drugs | 5 | 2019 | 13 | 2.490 |
Why?
|
| Bipolar Disorder | 5 | 2019 | 11 | 2.460 |
Why?
|
| Analgesics, Non-Narcotic | 3 | 2024 | 6 | 2.340 |
Why?
|
| Weight Gain | 6 | 2024 | 28 | 2.150 |
Why?
|
| Female | 57 | 2024 | 2811 | 2.150 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 5 | 2021 | 25 | 2.140 |
Why?
|
| Male | 53 | 2024 | 2765 | 2.070 |
Why?
|
| Health Services Accessibility | 4 | 2023 | 28 | 2.000 |
Why?
|
| Depressive Disorder, Major | 3 | 2021 | 18 | 1.920 |
Why?
|
| Body Mass Index | 7 | 2024 | 100 | 1.680 |
Why?
|
| Metformin | 2 | 2023 | 9 | 1.680 |
Why?
|
| Depression | 13 | 2020 | 133 | 1.680 |
Why?
|
| Hypertension | 7 | 2022 | 61 | 1.560 |
Why?
|
| Anti-Asthmatic Agents | 2 | 2022 | 3 | 1.490 |
Why?
|
| Dementia | 12 | 2021 | 77 | 1.480 |
Why?
|
| Asthma | 2 | 2022 | 11 | 1.480 |
Why?
|
| Aged | 45 | 2024 | 859 | 1.450 |
Why?
|
| Nursing Homes | 13 | 2019 | 33 | 1.450 |
Why?
|
| Antidepressive Agents | 4 | 2019 | 14 | 1.440 |
Why?
|
| Medicare | 18 | 2024 | 79 | 1.400 |
Why?
|
| Medication Adherence | 10 | 2024 | 70 | 1.380 |
Why?
|
| Healthcare Disparities | 3 | 2019 | 18 | 1.370 |
Why?
|
| Mental Disorders | 3 | 2023 | 52 | 1.320 |
Why?
|
| Polypharmacy | 3 | 2019 | 11 | 1.230 |
Why?
|
| Psychotic Disorders | 2 | 2021 | 4 | 1.130 |
Why?
|
| Diabetes Mellitus | 3 | 2023 | 33 | 1.070 |
Why?
|
| Drug Prescriptions | 4 | 2023 | 26 | 1.060 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2023 | 47 | 1.040 |
Why?
|
| Prescriptions | 2 | 2024 | 19 | 0.990 |
Why?
|
| Qualitative Research | 1 | 2024 | 47 | 0.870 |
Why?
|
| Aged, 80 and over | 23 | 2024 | 320 | 0.860 |
Why?
|
| Acute Pain | 1 | 2023 | 4 | 0.850 |
Why?
|
| Texas | 8 | 2022 | 190 | 0.850 |
Why?
|
| Pneumonia | 4 | 2020 | 20 | 0.840 |
Why?
|
| Hyperglycemia | 1 | 2023 | 10 | 0.820 |
Why?
|
| Managed Care Programs | 3 | 2022 | 7 | 0.810 |
Why?
|
| Hypertriglyceridemia | 1 | 2022 | 3 | 0.780 |
Why?
|
| Insulin Resistance | 1 | 2022 | 9 | 0.780 |
Why?
|
| Metabolic Syndrome | 1 | 2022 | 8 | 0.770 |
Why?
|
| Cholinergic Antagonists | 6 | 2019 | 20 | 0.770 |
Why?
|
| Child Psychiatry | 2 | 2024 | 6 | 0.760 |
Why?
|
| Psychiatry | 1 | 2021 | 2 | 0.720 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2021 | 4 | 0.720 |
Why?
|
| Emergency Service, Hospital | 4 | 2024 | 12 | 0.710 |
Why?
|
| Cohort Studies | 17 | 2022 | 131 | 0.700 |
Why?
|
| Urinary Bladder, Overactive | 4 | 2021 | 13 | 0.690 |
Why?
|
| Child, Preschool | 4 | 2024 | 187 | 0.670 |
Why?
|
| Risk Factors | 8 | 2024 | 184 | 0.670 |
Why?
|
| Obesity | 4 | 2023 | 118 | 0.660 |
Why?
|
| Central Nervous System Stimulants | 2 | 2017 | 9 | 0.650 |
Why?
|
| Blood Glucose | 3 | 2023 | 31 | 0.630 |
Why?
|
| Quality of Health Care | 1 | 2019 | 5 | 0.620 |
Why?
|
| Geography | 1 | 2019 | 7 | 0.620 |
Why?
|
| Hospitalization | 6 | 2024 | 38 | 0.620 |
Why?
|
| Homes for the Aged | 5 | 2017 | 11 | 0.620 |
Why?
|
| Physicians | 1 | 2019 | 18 | 0.600 |
Why?
|
| Minority Groups | 1 | 2019 | 39 | 0.600 |
Why?
|
| Antihypertensive Agents | 4 | 2020 | 16 | 0.590 |
Why?
|
| Mental Health Services | 1 | 2018 | 13 | 0.570 |
Why?
|
| Proportional Hazards Models | 11 | 2020 | 30 | 0.570 |
Why?
|
| Medicare Part C | 7 | 2024 | 31 | 0.550 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2017 | 3 | 0.540 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2017 | 4 | 0.540 |
Why?
|
| Physicians, Primary Care | 1 | 2017 | 8 | 0.540 |
Why?
|
| Paroxetine | 4 | 2017 | 8 | 0.510 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2022 | 21 | 0.500 |
Why?
|
| Risk | 11 | 2017 | 34 | 0.490 |
Why?
|
| Infant | 3 | 2023 | 87 | 0.490 |
Why?
|
| Substance-Related Disorders | 3 | 2023 | 52 | 0.460 |
Why?
|
| Breast Neoplasms | 3 | 2023 | 107 | 0.460 |
Why?
|
| Atrial Fibrillation | 2 | 2024 | 15 | 0.440 |
Why?
|
| Affect | 1 | 2014 | 30 | 0.420 |
Why?
|
| Antirheumatic Agents | 2 | 2023 | 6 | 0.420 |
Why?
|
| Case-Control Studies | 7 | 2023 | 96 | 0.420 |
Why?
|
| Cost-Benefit Analysis | 3 | 2024 | 20 | 0.420 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2023 | 12 | 0.410 |
Why?
|
| Analgesics | 2 | 2024 | 7 | 0.410 |
Why?
|
| Middle Aged | 15 | 2023 | 1098 | 0.410 |
Why?
|
| Cholesterol | 2 | 2023 | 18 | 0.400 |
Why?
|
| Mortality | 1 | 2012 | 3 | 0.400 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2023 | 26 | 0.390 |
Why?
|
| Cardiovascular Diseases | 2 | 2023 | 44 | 0.390 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 27 | 0.380 |
Why?
|
| Linear Models | 2 | 2023 | 60 | 0.350 |
Why?
|
| Young Adult | 5 | 2024 | 850 | 0.350 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 97 | 0.350 |
Why?
|
| Alzheimer Disease | 2 | 2022 | 90 | 0.330 |
Why?
|
| Primary Health Care | 2 | 2021 | 46 | 0.330 |
Why?
|
| Heart Failure | 3 | 2015 | 32 | 0.330 |
Why?
|
| Prescription Drugs | 3 | 2019 | 15 | 0.320 |
Why?
|
| Smoking Cessation | 3 | 2016 | 137 | 0.320 |
Why?
|
| Drug Therapy, Combination | 7 | 2023 | 26 | 0.300 |
Why?
|
| Health Personnel | 2 | 2019 | 22 | 0.300 |
Why?
|
| Infant, Newborn | 2 | 2019 | 49 | 0.300 |
Why?
|
| Treatment Outcome | 6 | 2023 | 212 | 0.290 |
Why?
|
| Parkinson Disease | 2 | 2020 | 89 | 0.290 |
Why?
|
| Cognition | 2 | 2023 | 174 | 0.280 |
Why?
|
| Cholinesterase Inhibitors | 3 | 2022 | 21 | 0.280 |
Why?
|
| Prescription Drug Monitoring Programs | 2 | 2017 | 7 | 0.280 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2024 | 8 | 0.270 |
Why?
|
| Markov Chains | 2 | 2024 | 18 | 0.270 |
Why?
|
| SEER Program | 2 | 2024 | 8 | 0.270 |
Why?
|
| Cognitive Dysfunction | 2 | 2019 | 66 | 0.260 |
Why?
|
| Adult | 10 | 2023 | 1683 | 0.250 |
Why?
|
| Bupropion | 2 | 2016 | 8 | 0.250 |
Why?
|
| Varenicline | 2 | 2016 | 8 | 0.250 |
Why?
|
| Risk Assessment | 3 | 2016 | 49 | 0.250 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 2016 | 5 | 0.250 |
Why?
|
| Propensity Score | 6 | 2017 | 11 | 0.250 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2016 | 37 | 0.230 |
Why?
|
| Incidence | 7 | 2019 | 33 | 0.230 |
Why?
|
| Autoimmune Diseases | 1 | 2024 | 6 | 0.230 |
Why?
|
| Drug Monitoring | 1 | 2024 | 10 | 0.230 |
Why?
|
| Factor Xa Inhibitors | 1 | 2024 | 5 | 0.230 |
Why?
|
| Rivaroxaban | 1 | 2024 | 6 | 0.230 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 10 | 0.230 |
Why?
|
| Pyridones | 1 | 2024 | 8 | 0.230 |
Why?
|
| Interviews as Topic | 1 | 2024 | 24 | 0.220 |
Why?
|
| Monte Carlo Method | 1 | 2024 | 17 | 0.220 |
Why?
|
| Fractures, Bone | 2 | 2016 | 8 | 0.220 |
Why?
|
| Time Factors | 2 | 2017 | 176 | 0.220 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 16 | 0.220 |
Why?
|
| Anticoagulants | 1 | 2024 | 15 | 0.220 |
Why?
|
| Pyrazoles | 1 | 2024 | 19 | 0.220 |
Why?
|
| Accidental Falls | 2 | 2016 | 16 | 0.220 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2024 | 2 | 0.220 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2015 | 16 | 0.220 |
Why?
|
| Aripiprazole | 1 | 2024 | 3 | 0.220 |
Why?
|
| Logistic Models | 3 | 2019 | 69 | 0.220 |
Why?
|
| Pharmacies | 1 | 2023 | 3 | 0.210 |
Why?
|
| Pain | 1 | 2024 | 40 | 0.210 |
Why?
|
| Stroke | 1 | 2024 | 53 | 0.210 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2023 | 12 | 0.210 |
Why?
|
| Biological Products | 1 | 2023 | 9 | 0.210 |
Why?
|
| Pharmaceutical Services | 1 | 2023 | 18 | 0.210 |
Why?
|
| Pharmacy | 1 | 2023 | 16 | 0.200 |
Why?
|
| Anti-Bacterial Agents | 3 | 2020 | 183 | 0.200 |
Why?
|
| Cross Infection | 2 | 2020 | 19 | 0.200 |
Why?
|
| Lipoproteins, HDL | 1 | 2022 | 3 | 0.200 |
Why?
|
| Obesity, Abdominal | 1 | 2022 | 6 | 0.200 |
Why?
|
| Mexico | 1 | 2022 | 19 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2023 | 13 | 0.190 |
Why?
|
| Hyperlipidemias | 1 | 2022 | 9 | 0.190 |
Why?
|
| Benzodiazepines | 3 | 2017 | 13 | 0.180 |
Why?
|
| Fingolimod Hydrochloride | 1 | 2021 | 9 | 0.180 |
Why?
|
| Aftercare | 1 | 2021 | 6 | 0.180 |
Why?
|
| HIV Infections | 1 | 2023 | 115 | 0.180 |
Why?
|
| Muscarinic Antagonists | 4 | 2021 | 18 | 0.170 |
Why?
|
| Comorbidity | 5 | 2020 | 49 | 0.170 |
Why?
|
| Health Care Costs | 1 | 2020 | 11 | 0.170 |
Why?
|
| Hepatic Encephalopathy | 1 | 2020 | 3 | 0.170 |
Why?
|
| Baths | 1 | 2020 | 1 | 0.170 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2020 | 2 | 0.170 |
Why?
|
| Drug Utilization | 1 | 2020 | 5 | 0.170 |
Why?
|
| Patient Readmission | 1 | 2020 | 7 | 0.170 |
Why?
|
| Multiple Sclerosis | 1 | 2021 | 46 | 0.160 |
Why?
|
| Critical Care | 1 | 2020 | 12 | 0.160 |
Why?
|
| Palliative Care | 1 | 2019 | 4 | 0.160 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 6 | 0.160 |
Why?
|
| Withholding Treatment | 1 | 2019 | 6 | 0.160 |
Why?
|
| Drug Utilization Review | 1 | 2019 | 2 | 0.150 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2019 | 6 | 0.150 |
Why?
|
| Quality Indicators, Health Care | 1 | 2019 | 3 | 0.150 |
Why?
|
| Blood Culture | 1 | 2019 | 1 | 0.150 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 1 | 0.150 |
Why?
|
| Gastroesophageal Reflux | 1 | 2019 | 2 | 0.150 |
Why?
|
| Equipment Contamination | 1 | 2019 | 3 | 0.150 |
Why?
|
| Blood Specimen Collection | 1 | 2019 | 4 | 0.150 |
Why?
|
| Proton Pump Inhibitors | 1 | 2019 | 4 | 0.150 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2019 | 12 | 0.150 |
Why?
|
| Body Weight | 1 | 2019 | 59 | 0.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 7 | 0.140 |
Why?
|
| Prescription Drug Misuse | 1 | 2017 | 9 | 0.140 |
Why?
|
| Controlled Substances | 1 | 2017 | 4 | 0.140 |
Why?
|
| Neoplasms | 1 | 2019 | 99 | 0.130 |
Why?
|
| Schizophrenic Psychology | 1 | 2016 | 3 | 0.130 |
Why?
|
| Schizophrenia | 1 | 2016 | 8 | 0.130 |
Why?
|
| Hip Fractures | 1 | 2016 | 3 | 0.130 |
Why?
|
| Suicide, Attempted | 1 | 2016 | 13 | 0.130 |
Why?
|
| Community-Acquired Infections | 1 | 2016 | 2 | 0.130 |
Why?
|
| Drug Combinations | 3 | 2020 | 25 | 0.120 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2015 | 3 | 0.120 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2015 | 17 | 0.120 |
Why?
|
| Nicotinic Agonists | 1 | 2015 | 14 | 0.120 |
Why?
|
| Febrile Neutropenia | 1 | 2015 | 2 | 0.120 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2015 | 4 | 0.120 |
Why?
|
| Dyslipidemias | 1 | 2015 | 4 | 0.120 |
Why?
|
| Depressive Disorder | 1 | 2015 | 12 | 0.120 |
Why?
|
| Tobacco Use Disorder | 1 | 2016 | 49 | 0.120 |
Why?
|
| Smoking | 1 | 2015 | 94 | 0.120 |
Why?
|
| Data Collection | 1 | 2013 | 15 | 0.110 |
Why?
|
| Methotrexate | 2 | 2023 | 5 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2023 | 6 | 0.100 |
Why?
|
| Receptor, ErbB-2 | 2 | 2023 | 17 | 0.100 |
Why?
|
| Administration, Oral | 2 | 2024 | 35 | 0.100 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 148 | 0.100 |
Why?
|
| Blood Vessels | 1 | 2012 | 8 | 0.100 |
Why?
|
| Housing | 1 | 2012 | 11 | 0.100 |
Why?
|
| Residence Characteristics | 1 | 2012 | 24 | 0.100 |
Why?
|
| Rivastigmine | 2 | 2022 | 6 | 0.100 |
Why?
|
| Galantamine | 2 | 2022 | 6 | 0.100 |
Why?
|
| Phenylcarbamates | 2 | 2022 | 5 | 0.090 |
Why?
|
| Indans | 2 | 2022 | 9 | 0.090 |
Why?
|
| Piperidines | 2 | 2022 | 17 | 0.090 |
Why?
|
| Survival Rate | 2 | 2023 | 16 | 0.090 |
Why?
|
| Decision Support Techniques | 2 | 2020 | 8 | 0.080 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 277 | 0.080 |
Why?
|
| Brain | 1 | 2012 | 286 | 0.080 |
Why?
|
| Age Factors | 2 | 2019 | 75 | 0.060 |
Why?
|
| Sex Factors | 2 | 2019 | 81 | 0.060 |
Why?
|
| Patient Acuity | 1 | 2023 | 4 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2023 | 3 | 0.050 |
Why?
|
| Medically Underserved Area | 1 | 2023 | 4 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2023 | 3 | 0.050 |
Why?
|
| Research | 1 | 2023 | 10 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2023 | 31 | 0.050 |
Why?
|
| Quetiapine Fumarate | 2 | 2012 | 2 | 0.050 |
Why?
|
| Dibenzothiazepines | 2 | 2012 | 2 | 0.050 |
Why?
|
| Risperidone | 2 | 2012 | 2 | 0.050 |
Why?
|
| Lipids | 1 | 2022 | 21 | 0.050 |
Why?
|
| Cholesterol, LDL | 1 | 2022 | 8 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2022 | 15 | 0.050 |
Why?
|
| Tolterodine Tartrate | 1 | 2021 | 2 | 0.050 |
Why?
|
| Acetylcholinesterase | 1 | 2021 | 4 | 0.040 |
Why?
|
| Injections | 1 | 2021 | 10 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 19 | 0.040 |
Why?
|
| Gastrointestinal Agents | 1 | 2020 | 2 | 0.040 |
Why?
|
| Lactulose | 1 | 2020 | 2 | 0.040 |
Why?
|
| Neomycin | 1 | 2020 | 2 | 0.040 |
Why?
|
| Administrative Claims, Healthcare | 1 | 2020 | 3 | 0.040 |
Why?
|
| Soaps | 1 | 2020 | 1 | 0.040 |
Why?
|
| Chlorhexidine | 1 | 2020 | 2 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2020 | 10 | 0.040 |
Why?
|
| Recurrence | 1 | 2020 | 26 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2020 | 17 | 0.040 |
Why?
|
| Cancer Pain | 1 | 2019 | 3 | 0.040 |
Why?
|
| Pain Management | 1 | 2019 | 14 | 0.040 |
Why?
|
| Hospital Costs | 1 | 2019 | 1 | 0.040 |
Why?
|
| Peptic Ulcer | 1 | 2019 | 2 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2019 | 40 | 0.040 |
Why?
|
| Deprescriptions | 1 | 2019 | 3 | 0.040 |
Why?
|
| Cost Savings | 1 | 2019 | 3 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2019 | 8 | 0.040 |
Why?
|
| Information Storage and Retrieval | 1 | 2019 | 13 | 0.040 |
Why?
|
| Prevalence | 1 | 2017 | 72 | 0.030 |
Why?
|
| Smoking Prevention | 1 | 2016 | 15 | 0.030 |
Why?
|
| Self-Injurious Behavior | 1 | 2016 | 8 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 32 | 0.030 |
Why?
|
| Medicare Part D | 1 | 2015 | 7 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2015 | 3 | 0.030 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2015 | 3 | 0.030 |
Why?
|
| Taxoids | 1 | 2015 | 4 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 9 | 0.030 |
Why?
|
| Causality | 1 | 2015 | 1 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 19 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2015 | 70 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 350 | 0.030 |
Why?
|
| Emergency Medical Services | 1 | 2012 | 4 | 0.020 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2012 | 7 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 2 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2012 | 132 | 0.020 |
Why?
|